Management of advance heart failure: a review

Archive ouverte

Kalmonovich, Eran | Audurier, Yohan | Akodad, Mariama | Mourad, Marc | Battistella, Pascal | Agullo, Audrey | Gaudard, Philippe | Colson, Pascal | Rouvière, Philippe | Albat, Bernard | Ricci, Jean-Etienne | Roubille, François

Edité par CCSD ; Expert Reviews -

International audience. Heart failure (HF) has become a global pandemic. Despite recent developments in both medical and device treatments, HF incidences continues to increase. The current definition of HF restricts itself to stages at which clinical symptoms are apparent. In advanced heart failure (AdHF), it is universally accepted that all patients are refractory to traditional therapies. As the number of HF patients increase, so does the need for additional treatments, with an increased proportion of patients requiring advanced therapies. Areas covered: This review discusses extensive evidence for the effect of medical treatment on HF, although the data on the effect on AdHF is scare. Authors review the relevant literature for treating AdHF patients. Furthermore, mechanical circulatory devices (MCD) have emerged as an alternative to heart transplantation and have been shown to enhance quality of life and reduce mortality therefore authors also review the current literature on the different MCD and technologies. Expert commentary: More patients will need advanced therapies, as the access to heart transplantation is limited by the number of available donors. AdHF patients should be identified timely since the window of opportunities for advanced therapy is narrow as their morbidity is progressive and survival is often short.

Consulter en ligne

Suggestions

Du même auteur

Idarucizumab (Praxbind ® ) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients

Archive ouverte | Kalmanovich, Eran | CCSD

International audience. Background: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surg...

Circulatory Support with Extracorporeal Membrane Oxygenation and/or Impella for Cardiogenic Shock During Myocardial Infarction

Archive ouverte | Mourad, Marc | CCSD

International audience. Temporary mechanical circulatory support (TCS) is recommended for patients with profound cardiogenic shock (CS). Extracorporeal membrane oxygenation (ECMO) and Impella are possible TCS device...

Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock

Archive ouverte | Gaudard, Philippe | CCSD

International audience

Chargement des enrichissements...